didanosine

Summary

Summary: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.

Top Publications

  1. ncbi Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells
    Brian L Robbins
    St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Pharmacotherapy 23:695-701. 2003
  2. pmc Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation
    P L Sharma
    Division of Infectious Disease, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 71:8846-51. 1997
  3. ncbi Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells
    Chul Kim
    Department of Cellular and Integrative Physiology, Indiana Center for Vascular Biology and Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    Antivir Ther 16:1335-9. 2011
  4. ncbi Selection and characterization of suitable lipid excipients for use in the manufacture of didanosine-loaded solid lipid nanoparticles and nanostructured lipid carriers
    Kasongo Wa Kasongo
    Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics, Freie Universitat Berlin, 12169 Berlin, Germany
    J Pharm Sci 100:5185-96. 2011
  5. ncbi High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin
    Ana Moreno
    Infectious Diseases, Hospital Ramon y Cajal, Universidad de Alcala de Henares, Madrid, Spain
    Antivir Ther 9:133-8. 2004
  6. ncbi L-carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1-infected subjects treated with zidovudine and didanosine
    Sonia Moretti
    Department of Experimental Medicine, University of L Aquila, Rome, Italy
    Antioxid Redox Signal 4:391-403. 2002
  7. ncbi Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Badalona, Spain
    Antivir Ther 9:335-42. 2004
  8. ncbi Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine
    Nicolas Merchante
    Hospital Universitario de Valme, Sevilla, Spain
    Antivir Ther 15:753-63. 2010
  9. pmc High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens
    Florence Doualla-Bell
    Botswana Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education, Gaborone, Botswana
    Antimicrob Agents Chemother 50:4182-5. 2006
  10. ncbi A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study
    J S Montaner
    Canadian HIV Trials Network, St Paul s Hospital University of British Colombia, Vancouver
    JAMA 279:930-7. 1998

Research Grants

Detail Information

Publications290 found, 100 shown here

  1. ncbi Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells
    Brian L Robbins
    St Jude Children s Research Hospital, Memphis, Tennessee 38105, USA
    Pharmacotherapy 23:695-701. 2003
    As tenofovir disoproxil fumarate substantially increases plasma concentrations of didanosine in patients with human immunodeficiency virus-1 infection, we sought to determine whether tenofovir and didanosine showed a similar intracellular ..
  2. pmc Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation
    P L Sharma
    Division of Infectious Disease, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    J Virol 71:8846-51. 1997
    ..mutation in human immunodeficiency virus type 1 reverse transcriptase (RT) develops as a consequence of didanosine (ddI) therapy and is associated with a decreased susceptibility to ddI...
  3. ncbi Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells
    Chul Kim
    Department of Cellular and Integrative Physiology, Indiana Center for Vascular Biology and Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    Antivir Ther 16:1335-9. 2011
    The use of abacavir and didanosine in HAART has been associated with an increased risk of myocardial infarction in HIV-infected patients...
  4. ncbi Selection and characterization of suitable lipid excipients for use in the manufacture of didanosine-loaded solid lipid nanoparticles and nanostructured lipid carriers
    Kasongo Wa Kasongo
    Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics, Freie Universitat Berlin, 12169 Berlin, Germany
    J Pharm Sci 100:5185-96. 2011
    ..of solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) loaded with the hydrophilic drug, didanosine (DDI)...
  5. ncbi High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin
    Ana Moreno
    Infectious Diseases, Hospital Ramon y Cajal, Universidad de Alcala de Henares, Madrid, Spain
    Antivir Ther 9:133-8. 2004
    Nucleoside analogues may induce mitochondrial toxicity, particularly didanosine. Ribavirin increases didanosine exposure, which might be clinically relevant when coadministered in HIV/HCV-coinfected patients.
  6. ncbi L-carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1-infected subjects treated with zidovudine and didanosine
    Sonia Moretti
    Department of Experimental Medicine, University of L Aquila, Rome, Italy
    Antioxid Redox Signal 4:391-403. 2002
    ..20 asymptomatic HIV-infected subjects with advanced immunodeficiency to receive either zidovudine (AZT), and didanosine (DDI) or the same regimen plus L-carnitine, a known antiapoptotic drug, for 7 months...
  7. ncbi Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Badalona, Spain
    Antivir Ther 9:335-42. 2004
    ..To assess the efficacy and safety of a once-daily antiretroviral regimen in HAART-experienced subjects with long-lasting viral suppression...
  8. ncbi Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine
    Nicolas Merchante
    Hospital Universitario de Valme, Sevilla, Spain
    Antivir Ther 15:753-63. 2010
    Unexpected cases of severe liver disease in HIV-infected patients have been reported and an association with didanosine (ddI) has been suggested. Transient elastography (TE) might detect patients harbouring such a condition...
  9. pmc High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens
    Florence Doualla-Bell
    Botswana Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education, Gaborone, Botswana
    Antimicrob Agents Chemother 50:4182-5. 2006
    ..of human immunodeficiency virus type 1 subtype C viruses isolated from 23 patients in Botswana treated with didanosine-based regimens...
  10. ncbi A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study
    J S Montaner
    Canadian HIV Trials Network, St Paul s Hospital University of British Colombia, Vancouver
    JAMA 279:930-7. 1998
    ..However, until recently, many drug combinations have not led to sustained suppression of HIV-1 RNA...
  11. pmc Clinically relevant genotype interpretation of resistance to didanosine
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Antimicrob Agents Chemother 49:1739-44. 2005
    We analyzed the didanosine (ddI) arm of the randomized, placebo-controlled Jaguar trial in order to define a genotypic score for ddI associated with virologic response...
  12. ncbi Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine
    Lambert Assoumou
    INSERM, U943, Paris, F 75013 France
    J Antimicrob Chemother 65:752-60. 2010
    ..Our aim was to investigate the respective role of statistical methodology and patients' baseline characteristics in the selection of mutations included in genotypic resistance scores...
  13. ncbi Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team
    J M Raboud
    Department of Health Care and Epidemiology, University of British Columbia, Vancouver, Canada
    J Acquir Immune Defic Syndr 22:260-6. 1999
    ..To determine whether baseline pVL is predictive of virologic response during the study periods...
  14. ncbi Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study
    F Garcia
    Infectious Diseases Unit, Institut d Investigacions Biomèdiques August Pi i Sunyer Hospital Clínic, Faculty of Medicine, University of Barcelona, Spain
    AIDS 14:2485-94. 2000
    To evaluate the safety and effectiveness of once-daily didanosine and nevirapine plus twice-daily stavudine versus twice-daily administration of all three drugs.
  15. ncbi Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients
    R Bucciardini
    Laboratory of Virology, Istituto Superiore di Sanita, Rome, Italy
    AIDS 14:2567-74. 2000
    To evaluate the quality of life outcomes in antiretroviral-naive patients randomized to zidovudine plus didanosine versus zidovudine plus didanosine plus nevirapine for treatment of advanced HIV disease (the Istituto Superiore di Sanità ..
  16. ncbi The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults
    F Raffi
    Department of Infectious Diseases, University Hospital Nantes, France
    Antivir Ther 5:267-72. 2000
    The virological and immunological efficacy of the triple regimen containing nevirapine (once or twice daily), didanosine (once daily) and stavudine, in antiretroviral-naive patients infected with HIV-1, was evaluated in an open-label, ..
  17. ncbi Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    Antivir Ther 11:693-9. 2006
    To determine the potential impact of reverse transcriptase (RT) mutations, other than those currently known to confer nucleoside reverse transcriptase inhibitors (NRTIs) resistance, on the virological response to didanosine (ddl).
  18. ncbi Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial
    Desmond Maitland
    Chelsea and Westminster Hospital, London, UK
    AIDS 19:1183-8. 2005
    ..safety and efficacy of two once-daily antiretroviral regimens containing lamivudine (3TC) or tenofovir disoproxil fumarate (TDF), each administered with didanosine (ddI) and efavirenz (EFV) as initial therapy to HIV-1-infected subjects.
  19. ncbi Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen
    Karine Lacombe
    Assistance Publique, Hopitaux de Paris, Hopital Saint Antoine, Service de Maladies Infectieuses et Tropicales, Paris F 75012, France
    AIDS 19:1107-8. 2005
    In this study, the dynamics of CD4 cell depletion during tenofovir/didanosine co-administration were analysed...
  20. ncbi Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response
    Lambert Assoumou
    Institut National de la Sante et de la Recherche Medicale, U720, Paris, France
    J Infect Dis 198:470-80. 2008
    This study was performed to investigate the concordance between commonly used human immunodeficiency virus type 1 (HIV-1) drug resistance interpretation systems for didanosine (ddI) and their ability to predict responses at weeks 8 and 24.
  21. ncbi Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine
    Agathe Leon
    Infectious Diseases Unit, Hospital Clinic, University of Barcelona, Spain
    AIDS 19:213-5. 2005
    ..a group of 14 antiretroviral-naive adults who initiated highly active antiretroviral therapy with tenofovir and didanosine plus efavirenz or nevirapine...
  22. pmc Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir
    Douglas Barnas
    Department of Medicine, Division Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA
    Antivir Ther 15:437-41. 2010
    ..We therefore investigated HIV-1 genotype and phenotype at the single genome level in samples from patients on a failing regimen of tenofovir (TNV), didanosine (ddI) and lamivudine (3TC).
  23. pmc Design and directed evolution of a dideoxy purine nucleoside phosphorylase
    David P Nannemann
    Department of Chemistry, Vanderbilt University, Nashville, TN 37235, USA
    Protein Eng Des Sel 23:607-16. 2010
    ..The engineered PNP may form the basis for catalysts and pathways for the biosynthesis of ddI...
  24. ncbi Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir
    Sabiha Hussain
    Pediatric Infectious Diseases and Immunology, University of Florida, Jacksonville, FL, USA
    Pediatr Nephrol 21:1034-6. 2006
    ..HIV-infected African-American girl who developed nephrogenic diabetes insipidus, renal insufficiency and Fanconi-like syndrome while taking tenofovir (Viread) in combination with lopinavir-ritonavir (Kaletra) and didanosine (Videx).
  25. ncbi Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir
    Urs Karrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, Switzerland
    AIDS 19:1987-94. 2005
    Antiretroviral therapy (ART) containing tenofovir disoproxil fumarate (TDF) and didanosine (ddI) has been associated with poor immune recovery despite virologic success...
  26. ncbi Submicron-size biodegradable polymer-based didanosine particles for treating HIV at early stage: an in vitro study
    Gurudutta Pattnaik
    Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India
    J Microencapsul 29:666-76. 2012
    ..The study was intended to develop poly(d,l-lactic-co-glycolic acid)-based nanoparticles containing didanosine and to observe their uptake by macrophages in vitro...
  27. pmc Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatment
    Deborah Hirt
    EA3620, Universite Paris Descartes, Paris, France
    Antimicrob Agents Chemother 53:4399-406. 2009
    Our objective was to study didanosine pharmacokinetics in children after the administration of tablets, the only formulation available in Burkina Faso for which data are missing, and to establish relationships between doses, plasma drug ..
  28. ncbi Presence of M184I/V in minor HIV-1 populations of patients with lamivudine and/or didanosine treatment failure
    V Svedhem
    Division of Infectious Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    HIV Med 8:504-10. 2007
    The aim of the study was to investigate the presence of M184I/V in minor HIV-1 populations of patients who failed lamivudine (3TC) and/or didanosine (ddI) treatment.
  29. ncbi Longitudinal study on mitochondrial effects of didanosine-tenofovir combination
    Sonia Lopez
    Mitochondrial Research Laboratory, Muscle Research Unit, Internal Medicine Department, Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain
    AIDS Res Hum Retroviruses 22:33-9. 2006
    ..We evaluate the effects of the introduction of TDF in a didanosine (ddI)-based highly active antiretroviral therapy (HAART) on mitochondrial DNA (mtDNA) content, mitochondrial ..
  30. pmc Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates
    S Palmer
    Center for AIDS Research at Stanford, Stanford University Medical Center, Stanford, California 94305 5107, USA
    Antimicrob Agents Chemother 43:2046-50. 1999
    ..In fixed combinations, both ddI and PMEA were synergistic with HU against wild-type and drug-resistant viruses...
  31. ncbi Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial
    Jean Michel Molina
    Assistance Publique Hopitaux de Paris, Paris, France
    J Infect Dis 191:830-9. 2005
    ..We assessed a once-daily combination to simplify therapy in patients infected with human immunodeficiency virus type 1 (HIV-1)...
  32. ncbi Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307
    Ian Frank
    AIDS Res Hum Retroviruses 20:916-26. 2004
    We performed a 24-week, placebo-controlled, comparative trial of hydroxyurea (HU) monotherapy, didanosine(ddI) monotherapy, and the combination of ddI plus HU administered as 1000 mg qd or 1500 mg qd in antiretroviral-naive and ..
  33. ncbi Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review
    Géraldine D'Ythurbide
    Department of Nephrology, Kremlin Bicetre Hospital, AP HP, Le Kremlin Bicetre, France
    Nephrol Dial Transplant 22:3656-9. 2007
  34. ncbi Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir
    Teresa Garcia-Benayas
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 22:333-7. 2006
    The combination of didanosine (ddI) and tenofovir (TDF) has potential advantages, but because of several pitfalls (unexpected decreases in CD4+ T cells, increased risk of pancreatitis) its use has been questioned...
  35. ncbi Didanosine extended-release matrix tablets: optimization of formulation variables using statistical experimental design
    Carla Sánchez-Lafuente
    Departamento de Farmacia y Tecnologia Farmaceutica, c Prof García González s n, 41012 Sevilla, Spain
    Int J Pharm 237:107-18. 2002
    ..the influence of some process and formulation variables and possible interactions among such variables, on didanosine release from directly-compressed matrix tablets based on blends of two insoluble polymers, Eudragit RS-PM and ..
  36. ncbi Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir
    Srinivasan Ramanathan
    Gilead Sciences, Foster City, CA 94404, USA
    J Acquir Immune Defic Syndr 46:160-6. 2007
    ..clinically relevant drug interactions between ritonavir-boosted elvitegravir (EVG/r) and the nucleoside reverse transcriptase inhibitors (NRTIs) zidovudine (ZDV), didanosine (ddI), stavudine (d4T), or abacavir (ABC) upon coadministration.
  37. ncbi Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021
    Ross E McKinney
    Department of Pediatrics, Duke University Medical Center, Box 3461, Durham, NC 27710, USA
    Pediatrics 120:e416-23. 2007
    ..Compliance with complex antiretroviral therapy regimens is a problem for HIV-1-infected children and their families. Simple, safe, and effective regimens are important for long-term therapeutic success...
  38. ncbi A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group
    J O Kahn
    San Francisco General Hospital, Calif 94110
    N Engl J Med 327:581-7. 1992
    ..b>Didanosine is another inhibitor of HIV reverse transcriptase...
  39. ncbi Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study
    Matilde Sanchez-Conde
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 23:1237-41. 2007
    The combination of didanosine (ddI) and lamivudine (3TC) is attractive considering its low cost, potency, tolerability, and convenience (once daily administration), but it is not recommended as first-line therapy for HIV infection...
  40. ncbi Intracellular activation of 2',3'-dideoxyinosine and drug interactions in vitro
    S Kewn
    Department of Pharmacology and Therapeutics, University of Liverpool, UK
    AIDS Res Hum Retroviruses 15:793-802. 1999
    b>Didanosine (2',3'-dideoxyinosine; ddI) requires intracellular metabolism to its active triphosphate, 2',3'-dideoxyadenosine 5'-triphosphate (ddATP), to inhibit the replication of human immunodeficiency virus (HIV)...
  41. ncbi Tolerability of enteric-coated didanosine capsules compared with didanosine tablets in adults with HIV infection
    L M Kunches
    JSI Clinical Research, Inc, Boston, Massachusetts 02210, USA
    J Acquir Immune Defic Syndr 28:150-3. 2001
    A new enteric-coated (EC) didanosine (ddI) formulation (Videx EC; Bristol-Myers Squibb, Princeton, NJ, U.S.A...
  42. ncbi Noncirrhotic portal hypertension associated with didanosine: a case report and literature review
    Hui min Chang
    Department of Pharmacy, Kaohsiung Veterans General Hospital, 386 Ta Chung First Rd, Kaohsiung, Taiwan
    Jpn J Infect Dis 65:61-5. 2012
    ..in human immunodeficiency virus (HIV)-infected patients and has been found to be associated with exposure to didanosine. Here, we describe the case of an HIV-infected patient with portal hypertension who initially presented with ..
  43. ncbi Formulation development and in vitro evaluation of didanosine-loaded nanostructured lipid carriers for the potential treatment of AIDS dementia complex
    Kasongo Wa Kasongo
    Department of Pharmaceutics, Biopharmaceutics and NutriCosmetics, Free University of Berlin, Berlin, Germany
    Drug Dev Ind Pharm 37:396-407. 2011
    The purpose of this article was to investigate the feasibility of incorporating didanosine (DDI) into nanostructured lipid carriers (NLC) for potential treatment of AIDS dementia complex...
  44. ncbi Direct analysis of mitochondrial toxicity of antiretroviral drugs
    A Foli
    Research Institute for Genetic and Human Therapy, IRCCS Policlinico S. Matteo, Pavia, Italy
    AIDS 15:1687-94. 2001
    ..of a cytofluorimetric technique to predict the mitochondrial-dependent pancreatic and hepatic toxicity we used didanosine (ddI) alone or in combination with hydroxyurea (HU)...
  45. ncbi Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine
    Carme Vidal
    Microbiology Laboratory, Institut Clínic de Infeccions i Immunologia, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Faculty of Medicine, University of Barcelona, Spain
    Antivir Ther 7:283-7. 2002
    ..patterns of resistance in a group of early-stage antiretroviral-naive patients failing initial therapy with didanosine, stavudine and nevirapine...
  46. ncbi Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma
    J A Sparano
    Department of Oncology, Albert Einstein Cancer Center, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA
    J Clin Oncol 14:3026-35. 1996
    To determine the following: (1) the feasibility of combining the antiretroviral didanosine (ddl) with a 96-hour continuous intravenous (IV) infusion of cyclophosphamide (800 mg/m2), doxorubicin (50 mg/m2), and etoposide (240 mg/m2) (CDE) ..
  47. pmc Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in [corrected] HIV/AIDS
    D De Forni
    ViroStatics, Sassari, Italy
    Br J Pharmacol 161:830-43. 2010
    ..VS411, a first-in-class AV-HALT, is a single-dosage form combining didanosine (ddI, 400 mg), an antiviral (AV), and hydroxyurea (HU, 600 mg), a cytostatic agent, designed to provide a slow ..
  48. ncbi Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir
    Heidi M Crane
    Department of Medicine, University of Washington, Seattle, Washington 98104, USA
    AIDS 21:1431-9. 2007
    ..To examine the effect of antiretroviral agents and clinical factors on the development of tenofovir-associated kidney dysfunction...
  49. ncbi Modeling the use of triple combination therapy in five countries: nevirapine, Zidovudine, and Didanosine
    A K Biddle
    Department of Health Policy and Administration, School of Public Health, University of North Carolina, Chapel Hill, NC, USA
    Value Health 3:186-201. 2000
    ..Standardized, detailed disclosure of model assumptions and parameters makes it possible to recycle published models with minor structural modifications to examine the efficiency of therapies based on new trial data...
  50. ncbi Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses
    Abeer M Al-Ghananeem
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA
    J Drug Target 18:381-8. 2010
    ..n.) administration as a potential route to enhance systemic and brain delivery of didanosine (ddI)...
  51. ncbi Tolerance of didanosine as enteric-coated capsules versus buffered tablets
    Pablo Barreiro
    Service of Infectious Diseases Hospital Carlos III Madrid, Spain
    AIDS Patient Care STDS 18:329-31. 2004
  52. ncbi The intestinal permeation of didanosine from granules containing microspheres using the everted gut sac model
    Classius Ferreira da Silva
    Biotechnological Processes Development Laboratory, School of Chemical Engineering, State University of Campinas UNICAMP, Campinas, SP, Brazil
    J Microencapsul 26:523-8. 2009
    ..aim of this research is to evaluate the intestinal permeation of a new formulation (NF) for the anti-retroviral didanosine (ddI) drug, using the everted gut sac model...
  53. ncbi Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets
    Lambert Assoumou
    INSERM U943, UPMC Univ Paris 06, UMR S 943, Paris, France
    AIDS 24:365-71. 2010
    To assess the genotypic determinants of the virological response to didanosine (ddI) in HIV-infected patients.
  54. ncbi The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine
    Michael Sproat
    St Stephens Centre, Chelsea and Westminster Healthcare NHS Trust, London, UK
    Antivir Ther 10:357-61. 2005
    ..studies suggest that the presence of the M184V mutation leads to a reduction in HIV-1 susceptibility to didanosine (ddl). The relevance of this to clinical outcomes remains unclear...
  55. ncbi Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine
    Ana Barrios
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 19:569-75. 2005
    Tenofovir (TDF) and didanosine (ddI) are both adenosine analogues with convenient posology, strong potency and a relatively high genetic barrier for resistance...
  56. ncbi Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients
    François Becher
    CEA, Pharmacology and Immunology Unit, DSV DRM, Gif sur Yvette, France
    AIDS 18:181-7. 2004
    To determine the concentrations of intracellular active anabolites of stavudine (d4T) and didanosine (DDI) and their interpatient variability in HIV-infected patients and to explore relationships between plasma and intracellular forms.
  57. ncbi Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine
    Florence Rollot
    Internal Medicine, Cochin and Saint Vincent de Paul Hospital, Paris, France
    Clin Infect Dis 37:e174-6. 2003
    ..Increased plasma concentrations of didanosine were also observed after the addition of tenofovir...
  58. ncbi Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks
    N I Paton
    Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore
    HIV Med 6:13-20. 2005
    To evaluate the long-term safety and efficacy of the combination of hydroxychloroquine, hydroxyurea and didanosine.
  59. ncbi Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors
    Tomas Cihlar
    Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94404, USA
    Antiviral Res 54:37-45. 2002
    ..In conclusion, tenofovir exhibited weak cytotoxic effects in all cell types tested with less in vitro cytotoxicity than the majority of NRTIs currently used for the treatment of HIV disease...
  60. ncbi Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir
    Mohammad M Hossain
    Department of Internal Medicine, Division of Infectious Diseases, North Texas Veterans Health Care Systems, Dallas, TX, USA
    Antiviral Res 55:41-52. 2002
    ..MPA exhibits anti-HIV activity in vitro. We tested MPA alone and in combination with abacavir (ABC), didanosine (DDI), lamivudine (3TC) and tenofovir (TFV) against wild-type human immunodeficiency virus type-1 (HIV-1) and ..
  61. ncbi Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial
    Jean Michel Molina
    Department of Infectious Diseases, Saint Louis Hospital, Paris, France
    J Infect Dis 191:840-7. 2005
    The antiviral efficacy of didanosine in patients experiencing virological failure is not well known.
  62. ncbi Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms
    Franco Lori
    Research Institute for Genetic and Human Therapy, IRCCS Policlinico S Matteo, Pavia, Italy and Washington, DC 2007, USA
    AIDS 19:1173-81. 2005
    The hydroxyurea-didanosine combination has been shown to limit immune activation (a major pathogenic component of HIV/AIDS) and suppress viral load by both antiviral and cytostatic ('virostatic') activities...
  63. ncbi Fanconi syndrome associated with didanosine therapy
    Hassane Izzedine
    AIDS 19:844-5. 2005
  64. ncbi Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation
    Carmen de Pablo
    Departamento de Farmacología and CIBERehd, Universidad de Valencia, Spain
    AIDS 24:1259-66. 2010
    Abacavir and didanosine are nucleoside reverse transcriptase inhibitors (NRTI) widely used in therapy for HIV-infection but which have been linked to cardiovascular complications...
  65. pmc A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people
    Jeffrey T Schouten
    Department of Surgery, University of Washington, Seattle, USA
    BMC Infect Dis 6:28. 2006
    ..The goal of this study was to conduct a prospective assessment of the contribution of zidovudine (ZDV) and didanosine (ddI) to hearing loss.
  66. pmc Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine
    Marc Lallemant
    Institut de Recherche pour le Développement U174, Universite Paris Descartes, Institut National d Etudes Demographiques, Institut de Recherche pour le Developpment, F 75006, Paris, France
    Clin Infect Dis 50:898-908. 2010
    ..We hypothesized that a 1-month zidovudine-didanosine course initiated at the same time as single-dose nevirapine (sdNVP) would prevent the selection of nevirapine-..
  67. pmc Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial
    Hermann Bussmann
    Botswana Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education BHP, Gaborone, Botswana
    J Acquir Immune Defic Syndr 51:37-46. 2009
    ..The "Tshepo" Study is the first large-scale, randomized, clinical trial that addresses these important issues among HIV-1 subtype C-infected ARV treatment-naive adults in southern Africa...
  68. ncbi Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine
    Andrea De Luca
    Institute of Clinical Infectious Diseases, Catholic University, Roma, 00168, Italy
    J Infect Dis 196:1645-53. 2007
    Consensus on the interpretation of mutations in the human immunodeficiency virus (HIV)-1 reverse transcriptase (RT) gene that predict the response to didanosine treatment is needed.
  69. ncbi Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz
    Katyna Borroto-Esoda
    Gilead Sciences, Inc, 4611 University Drive, Durham, North Carolina 27707, USA
    AIDS Res Hum Retroviruses 23:988-95. 2007
    ..response in treatment-naive patients to therapy with emtricitabine (FTC) or stavudine (d4T) in combination with didanosine (ddI) and efavirenz (EFV)...
  70. ncbi Development of sustained release matrix tablets of didanosine containing methacrylic and ethylcellulose polymers
    Carla Sánchez-Lafuente
    Departamento de Farmacia y Tecnologia Farmaceutica, Sevilla, Spain
    Int J Pharm 234:213-21. 2002
    b>Didanosine, a nucleoside analog used in the treatment of acquired immuno deficiency syndrome (AIDS), has been incorporated into directly compressed monolythic matrices whose excipients were mixtures at different ratios of a methacrylic ..
  71. ncbi Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: in vitro and in vivo evaluation
    Amandeep Kaur
    Department of Pharmaceutical Sciences, Drug Research Punjabi University, Patiala, Punjab, 147 002, India
    Acta Pharm 58:61-74. 2008
    ..The objective of the present study was to investigate mannan-coated nanoparticles for macrophage targeting of didanosine. Different didanosine loaded nanoparticles were prepared using the double desolvation technique and were ..
  72. ncbi Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF
    Stefania Notari
    Istituto Nazionale per le Malattie Infettive IRCCS Lazzaro Spallanzani, Via Portuense 292, I 00149 Roma, Italy
    J Chromatogr B Analyt Technol Biomed Life Sci 863:249-57. 2008
    ..Here, we apply MALDI-TOF/TOF technology to quantify abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine in the plasma of HIV-infected patients, by standard additions analysis...
  73. ncbi Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
    Juan Berenguer
    Hospital Gregorio Maranon, Madrid, Spain
    Clin Infect Dis 47:1083-92. 2008
    The combination of didanosine, lamivudine, and efavirenz (ddI/3TC/EFV) for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection has been insufficiently analyzed in clinical trials.
  74. ncbi Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load
    Eugenia Negredo
    Lluita contra la SIDA and Irsicaixa Foundations Germans Trias i Pujol Hospital, Badalona, Spain
    AIDS 18:459-63. 2004
    We recently observed a significant CD4 cell count decline in patients receiving didanosine (ddI) 400 mg, tenofovir (TDF) and nevirapine (NVP), despite virological suppression.
  75. ncbi Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine
    Melissa D Murphy
    Infectious Disease Section, Veterans Affairs Medical Center, and Oregon Health and Science University, Portland, Oregon 97201, USA
    Clin Infect Dis 36:1082-5. 2003
    ..lactic acidosis and who died several weeks after tenofovir was added to an antiretroviral regimen that included didanosine. Although the role of tenofovir in precipitating acute renal failure is unclear, progressive accumulation of the ..
  76. ncbi Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir
    Pablo Barreiro
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 57:806-9. 2006
    ..As an example, the combination of didanosine and tenofovir has recently been associated with a paradoxical depletion of CD4+ T cells in the face of complete ..
  77. ncbi Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Spain
    Clin Infect Dis 41:901-5. 2005
    The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T-20 ..
  78. ncbi Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial
    Ana Barrios
    Department of Infectious Diseases, Hospital Carlos III, Madrid
    Antivir Ther 10:825-32. 2005
    ..on HAART and with plasma HIV-1 RNA <50 copies/ml for longer than 6 months were switched to tenofovir, didanosine and efavirenz (QD arm) or remained on the same treatment regimen (control arm)...
  79. ncbi Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial)
    J M Molina
    Department of Infectious Diseases, Hopital Saint Louis, Paris, France
    HIV Med 5:99-104. 2004
    This study was conducted to investigate the pharmacokinetics of emtricitabine (FTC), didanosine (ddI), and efavirenz (EFV) when administered in a once-daily combination.
  80. ncbi Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons
    R D MacArthur
    Department of Medicine, Division of Infectious Diseases, Wayne State University, Detroit, Michigan 48201, USA
    HIV Clin Trials 5:361-70. 2004
    The combination of abacavir + lamivudine (ABC+3TC) versus didanosine + stavudine (ddI+d4T), each combined with other classes of antiretrovirals (ARVs) in ARV-naive patients, was compared for the combined endpoint of time to plasma HIV RNA ..
  81. ncbi Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects
    Ian Sanne
    Department of Infectious Diseases and Clinical Microbiology, University of Witwatersrand Johannesburg, South Africa
    J Acquir Immune Defic Syndr 32:18-29. 2003
    ..were compared with nelfinavir (750 mg three times daily) when given both as monotherapy and in combination with didanosine and stavudine in 420 antiretroviral-naive subjects infected with HIV-1...
  82. ncbi Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases
    Joan M Irizarry-Alvarado
    Division of General Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA
    AIDS Read 19:114-21. 2009
    ..insipidus developed secondary to use of an antiretroviral regimen containing tenofovir disoproxil fumarate and didanosine. These patients presented with a history of polydipsia, polyuria, weight loss, anorexia, and wasting...
  83. ncbi Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine
    Jan Gerstoft
    Department of Infectious Diseases at Rigshospitalet, Copenhagen, Denmark
    AIDS 17:2045-52. 2003
    ..Highly active antiretroviral therapy containing three nucleoside reverse transcriptase inhibitors has been somewhat successful, but the clinical efficacy is unclear...
  84. ncbi Didanosine: an updated review of its use in HIV infection
    C M Perry
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 58:1099-135. 1999
    b>Didanosine, like zidovudine, stavudine and lamivudine, is a nucleoside analogue reverse transcriptase inhibitor (NRTI)...
  85. ncbi Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy
    Jintanat Ananworanich
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    J Antimicrob Chemother 61:1340-3. 2008
    ..Here, we evaluated the effect of switching from stavudine/didanosine to tenofovir/lamivudine on measures of metabolic and mitochondrial toxicity in Thai patients.
  86. ncbi Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in mice treated neonatally with zidovudine and didanosine
    Linda S Von Tungeln
    Division of Biochemical Toxicology and Division of Genetic and Reproductive Toxicology, National Center for Toxicological Research, Jefferson, AR 72079, USA
    Mutagenesis 19:307-11. 2004
    ..A previous study indicated that the anti-retroviral agent didanosine (2',3'-dideoxyinosine, ddI) potentiated the mutagenicity of AZT in the thymidine kinase (TK) gene of cultured ..
  87. ncbi A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection
    Mark Dybul
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States Department of Health and Human Services, Bethesda, Maryland 20892, USA
    J Infect Dis 189:1974-82. 2004
    ..Adherence to such a regimen may be problematic for certain patients...
  88. ncbi Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine
    Ulrich A Walker
    Medizinische Universitatsklinik, Department of Clinical Immunology, Freiburg, Germany
    Hepatology 39:311-7. 2004
    The "D drug" HIV reverse-transcriptase inhibitors zalcitabine, didanosine, and stavudine are relatively strong inhibitors of polymerase-gamma compared with the "non-D drugs" zidovudine, lamivudine, and abacavir...
  89. ncbi Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir
    F Lori
    RIGHT, Medical Dental Bldg SW307, Washington, DC 20007, USA
    J Infect Dis 180:1827-32. 1999
    ..during acute HIV infection before complete Western blot (WB) seroconversion with the combination of hydroxyurea, didanosine, and indinavir. This treatment was associated with the normalization of some immune parameters and functions...
  90. ncbi Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease
    Christopher N Mayhew
    Department of Clinical Sciences, University of Kentucky Medical Center, Lexington, KY, USA
    Antiviral Res 65:13-22. 2005
    ..trimidox (3,4,5-trihydroxybenzamidoxime) and didox (3,4-dihydroxybenzohydroxamic acid) in combination with didanosine (2,3-didoxyinosine; ddI) in the LPBM5 MuLV retrovirus model (murine AIDS)...
  91. ncbi Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naïve patients: the VESD study
    J Santos
    Infectious Diseases Unit, Hospital Virgen de la Victoria, Malaga, Spain
    HIV Clin Trials 6:320-8. 2005
    Our aim was to analyze the efficacy and safety of didanosine-lamivudine-efavirenz in a cohort of HIV patients starting antiretroviral therapy between January and September 2003.
  92. ncbi Peripheral neuropathy during stavudine-didanosine antiretroviral therapy
    V Reliquet
    Department of Infectious Diseases, University Hospital, Nantes, France
    HIV Med 2:92-6. 2001
    ..We investigated the incidence, evolution and predictive factors of PN during stavudine (d4T)-didanosine (ddI) combination therapy in 65 HIV infected patients, previously treated with zidovudine and/or zalcitabine (..
  93. ncbi A simplified weight-based method for pediatric drug dosing for zidovudine and didanosine in resource-limited settings
    Paul J Weidle
    Division of HIV AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Pediatr Infect Dis J 25:59-64. 2006
    Zidovudine and didanosine are antiretroviral drugs used for human immunodeficiency virus (HIV)-infected children with dose recommendations based on body surface area calculations...
  94. ncbi Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine
    V Picard
    Laboratory of Virology, , Paris, France
    J Infect Dis 184:781-4. 2001
    ..assays were performed on paired isolates from antiretroviral drug-naive patients randomized to stavudine and didanosine (group 1; n = 21) or zidovudine and lamivudine (group 2; n = 21) at baseline and after > or = 12 months of ..
  95. ncbi Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine
    B Conway
    Department of Pharmacology and Therapeutics, University of British Columbia, Vancouver, Canada
    AIDS 15:1269-74. 2001
    OBJECTIVE: To evaluate the development of phenotypic and genotypic resistance to zidovudine, didanosine and nevirapine as a function of the virologic response to therapy in a group of drug-naive individuals receiving various combinations ..
  96. ncbi Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients
    G J Claas
    Medizinische Poliklinik der LMU München, Pettenkoferstrasse 8a, 80336 Munich, Germany
    Eur J Med Res 12:54-60. 2007
    Nucleoside analogues such as Didanosine and Stavudine are known to cause metabolic and body habitus changes during antiretroviral therapy...
  97. ncbi Oral sustained-release bioadhesive tablet formulation of didanosine
    G V Betageri
    Western University of Health Sciences, Pomona, California 91766, USA
    Drug Dev Ind Pharm 27:129-36. 2001
    ..of this study was to formulate a hydrogel-forming bioadhesive drug delivery system for oral administration of didanosine (ddI)...
  98. ncbi Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial)
    Jean Michel Molina
    Assistance Publique Hopitaux de Paris, Hopital Saint Louis, Department of Infectious Diseases, University of Paris 7, France
    Antivir Ther 12:417-22. 2007
    Once-daily combination therapy with emtricitabine, didanosine and efavirenz has been highly effective in clinical trials but its long-term efficacy and safety has not been previously reported.
  99. pmc Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients
    Alain Pruvost
    CEA, Service de Pharmacologie et d Immunologie, DSV DRM, CEA Saclay, 91191 Gif sur Yvette Cedex, France
    Antimicrob Agents Chemother 49:1907-14. 2005
    Recent work has demonstrated the existence of a systemic interaction between didanosine (ddI) and tenofovir disoproxyl fumarate (TDF) that leads to a significant increase in plasma ddI levels when coadministered with TDF (40 to 50% ..
  100. ncbi Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1
    Nicholas I Paton
    Department of Infectious Diseases, Tan Tock Seng Hospital, 308433, Singapore
    Lancet 359:1667-8. 2002
    ..CD4 count >150 cells/microL) with hydroxychloroquine (200 mg), hydroxycarbamide (hydroxyurea) (500 mg), and didanosine (125-200 mg), taken twice daily. Treatment was well tolerated, with few serious adverse events...
  101. ncbi Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study
    Helen Kovari
    Divisions of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich CH 8091, Switzerland
    Clin Infect Dis 49:626-35. 2009
    ..Postulated pathogenesis includes prolonged exposure to antiretroviral therapy, particularly didanosine.

Research Grants62

  1. Drug Transport at the Blood-Testis Barrier
    Nathan J Cherrington; Fiscal Year: 2013
    ..the functional capacity and molecular specificity of isolated Sertoli cells and intact STs to transport NSAs (didanosine, azidothymidine, abacavir, emtricitabine, tenofovir) and PIs (lopinavir and indinavir)...
  2. Nucleoside Transporters In HAART Mitochondrial Toxicity
    John Buolamwini; Fiscal Year: 2006
    ..These nucleoside drugs, including zidovudine (AZT), stavudine (d4T), didanosine (DDI), zalcitabine (DDC) and lamivudine (3TC) are believed to cause mitochondria! depletion to varying extents, ..
  3. CENTRAL NERVOUS SYSTEM STRATEGIES TARGETING THE HIV SANC
    Bradley Anderson; Fiscal Year: 2003
    ..In aim 2 we will test the hypothesis that significantly higher CNS concentrations of anti-HIV agents (didanosine and indinavir) can be attained in combination therapy by modulation of the BBB to inhibit protease inhibitor ..
  4. Auditory Perception of Drug Names: Neighborhood Effects
    Bruce Lambert; Fiscal Year: 2006
    ..abstract_text> ..
  5. Nanodelivery of active NRTI to the central nervous system: humanized HIV murine m
    Serguei Vinogradov; Fiscal Year: 2009
    ..of viral load in cultured macrophages by antiviral NAs or nanogel-NATP formulations, using the neurotoxic NRTI, didanosine (ddI), and zidovudine (AZT), and their derivatives, ddI-TP and AZT-TP...
  6. HIV-1 resistance to nucleoside analogues
    Daniel Kuritzkes; Fiscal Year: 2004
    ..PMPA; and 5) to explore the effect of other "AZT-sensitizing" mutations (such as those encoding resistance to didanosine [L74V] and nevirapine [Y181C] on pyrophosphorolysis and primer unblocking...
  7. TECHNOLOGY FOR IMPROVED ORAL DELIVERY OF ANTI-HIV DRUGS
    GLEN LEESMAN; Fiscal Year: 1992
    ..This strategy could reduce patient toxicity, thus improving and prolonging oral therapy...
  8. Endothelial Dysfunction Due to HIV-1 Protease Inhibitors
    Mitchell Goldman; Fiscal Year: 2006
    ..abstract_text> ..
  9. Lipodystrophy among HIV-infected patients
    Heidi Crane; Fiscal Year: 2008
    ..abstract_text> ..
  10. The Impact of HLA in Children Receiving HAART
    Akihiko Saitoh; Fiscal Year: 2008
    ..This research will also suggest modes of pathogenesis that can lead to the development of vaccine strategies. ..
  11. Predictors of Immunologic Long-term Non-Progression in Children with HIV
    Jintanat Ananworanich; Fiscal Year: 2010
    ..This will be important in deciding when to treat children with antiretroviral therapy. ..
  12. NEW ENGLAND PROGRAM FOR AIDS CLINICAL TRIALS-PROACT (CPC
    Gerald Friedland; Fiscal Year: 2006
    ..Among the three ProACT sites we will enroll and follow 200 patients on study protocols at any given time over the course of this grant. ..
  13. PROTEASE INHIBITOR RELATED ATHEROSCLEROSIS IN HIV
    Andrew Carr; Fiscal Year: 2005
    ....
  14. Integrated Human Research Subjects Protection Project
    Ross McKinney; Fiscal Year: 2003
    ..abstract_text> ..
  15. CARDIAC DYSFUNCTION, AIDS AND COCAINE
    William Lewis; Fiscal Year: 2003
    ..Immuno-LM and immuno-TEM identify cellular and subcellular alterations. ..
  16. Mitochondrial Genomics and Peripheral Neuropathy during HIV Therapy
    Todd Hulgan; Fiscal Year: 2008
    ..Results from this study will also advance the field of "mitochondrial medicine", having broad application across other scientific disciplines and for other human diseases. [unreadable] [unreadable] [unreadable]..
  17. Safety Pharmacokinetics & Efficacy of Artemether & Lumefantrine in Pregnant Women
    Mark Mirochnick; Fiscal Year: 2008
    ..The data from this planned study will provide the information needed to ensure that pregnant women receive the appropriate doses of these anti-malaria drugs. [unreadable] [unreadable] [unreadable]..
  18. ADULT AIDS CLINICAL TRIALS GROUP
    Michael Saag; Fiscal Year: 2007
    ..abstract_text> ..
  19. Oxidant Stress and Antioxidants during HIV Therapy
    Todd Hulgan; Fiscal Year: 2007
    ..The candidate's long-term goal is to develop into an independent clinical investigator in this field of study. ..
  20. RECENT ADVANCES IN AIDS AND HIV RESEARCH
    Michael Saag; Fiscal Year: 2007
    ..CME credit for attending physicians will be provided. ..
  21. Sleep Studies in HIV+ Older Children/Adolescents
    William Shearer; Fiscal Year: 2007
    ....
  22. HIV-Related Proteinuria and Endothelial Dysfunction
    Samir Gupta; Fiscal Year: 2007
    ..Dub6) in the fields of HIV metabolic and renal complications, renal vascular and glomerular pathology, and clinical trials design and implementation. ..
  23. Statistical Methods for Analysis of Array CGH Data
    Rebecca Betensky; Fiscal Year: 2007
    ..Sound statistical methods are required for efficient and valid analyses of these important data. [unreadable] [unreadable]..
  24. Antiretroviral Therapy and the Hepatitis C Virus
    Kenneth E Sherman; Fiscal Year: 2010
    ....
  25. Monitoring HAART in HIV-infected parents in Thailand
    Marc Lallemant; Fiscal Year: 2008
    ..A secondary endpoint is the number of drugs exhausted, taking into account cross-resistance mutations and shared toxicities. A pilot pharmacokinetic sub study will evaluate drug levels in the study population. ..
  26. Statistical Methods for the Analysis of Functional Genomic Data
    Debashis Ghosh; Fiscal Year: 2008
    ..unreadable] 5. Dissemination of these results in user-friendly statistical software. ..
  27. Acquired mtDNA depletion and nucleoside reverse transciptase inhibitors
    William Lewis; Fiscal Year: 2010
    ..Experiments offer insights into improving therapy with antiretrovirals used in AIDS. ..
  28. Assessment of Infant Outcomes After in Utero Exposure to Antiretroviral Therapy
    Sonia Hernandez diaz; Fiscal Year: 2010
    ..We propose to evaluate the risk of congenital malformations and other adverse pregnancy outcomes following antenatal exposure to ART in a prospective cohort of pregnant women. ..
  29. Standard zidovudine plus infant nevirapine to prevent perinatal HIV in Thailand
    Marc J Lallemant; Fiscal Year: 2010
    ....
  30. Understanding Patient Expectations of Treatment Outcomes
    KEVIN P contact WEINFURT; Fiscal Year: 2010
    ..abstract_text> ..
  31. CARDIOMYOPATHY IN AIDS
    William Lewis; Fiscal Year: 2009
    ..HYPOTHESIS 4: mtDNA depletion (from any above) causes or results from oxidative stress. Antioxidants ameliorate oxidative stress from NRTIs by decreasing oxidation of mtDNA. ..
  32. Integrating HIV Resistance Data into the CNICS Cohort
    James Kahn; Fiscal Year: 2004
    ..In this application we focus on adding the new data elements of viral resistance to the CNICS research network..
  33. NEVIRAPINE+ZIDOVUDINE--PREVENT PERINATAL HIV IN THAILAND
    Marc Lallemant; Fiscal Year: 2002
    ....
  34. STATISTICAL METHODS FOR ANALYSIS OF FAILURE TIME DATA
    Rebecca Betensky; Fiscal Year: 2009
    ..The methods may lead to faster discovery of cancer genes and effective treatments and to better understanding of disease progression through more efficient use of resources. ..
  35. True prevalence of pre-existing reverse transcriptase inhibitor resistance in tre
    Rafael Campo; Fiscal Year: 2008
    ..Most importantly, unrecognized resistance might impair the efficacy of antiretroviral therapy, and its timely identification could lead to better treatment outcomes. [unreadable] [unreadable] [unreadable]..
  36. Hepatic mitochondrial oxidative stress, AIDS and alcohol
    William Lewis; Fiscal Year: 2005
    ..Biochemical, molecular and pathological changes (above) are ameliorated. This serves as a "proof of principle". ..
  37. Statistical Methods of Cardiotoxicity Studies in Aids
    Stuart Lipsitz; Fiscal Year: 2007
    ..abstract_text> ..
  38. Antiretroviral Pharmacology/Lactating Mother/Infants
    Mark Mirochnick; Fiscal Year: 2006
    ..This information is needed for the safe and effective use of antiretrovirals in nursing women, and will pioneer a novel approach to the study of breast milk drug transfer. ..
  39. AIDS and Alcohol and Cardiomyopathy
    William Lewis; Fiscal Year: 2005
    ..Myofibrillar, nuclear and mitochondrial volumes are analyzed quantitatively (by transmission electron microscopy [TEM]). Volume fractions of extracellular matrix and of myocytes are determined morphometrically (light and TEM). ..
  40. Observational Cohort of HIV-Infected Persons
    James Kahn; Fiscal Year: 2005
    ..Dr. Kahn's research program has the enthusiastic support of his deuartment. the leadership of the AIDS Research Institute at UCSF and other nationally recognized clinical researchers. ..
  41. Drug Resistance in Non-Subtype B HIV-1
    Susan Eshleman; Fiscal Year: 2005
    ..abstract_text> ..
  42. Alcohol and HIV Progression in the Hopkins HIV Cohort
    Richard Moore; Fiscal Year: 2005
    ..We believe that our research will yield valuable results to better understand the relationship between alcohol use and HIV/AIDS. ..
  43. Polymorphism of Multi-Drug-Resistance Protein-1
    RODNEY HO; Fiscal Year: 2005
    ....
  44. Semiparametric Regression Analysis of Censored Data
    Danyu Lin; Fiscal Year: 2004
    ..Applications to real medical studies will be provided. The research results will be disseminated to practicing statisticians and medical investigators via publications, lectures and software distributions. ..
  45. COGNITIVE NEUROPSYCHOLOGY OF HIV AND MDMA ABUSE
    Eileen Martin; Fiscal Year: 2004
    ....
  46. Statistical Methods for Analysis of Quantitative LOH
    Rebecca Betensky; Fiscal Year: 2004
    ..A secondary goal of this proposal is to identify and apply unbiased tests for linkage between marker loci and a gene with functional significance. ..
  47. A cell-based assay to measure HCV drug susceptibility
    Neil Parkin; Fiscal Year: 2004
    ....
  48. NK CELL ADCC AND CD4+ CELL APOPTOSIS IN HIV+ TISSUES
    Gail Skowron; Fiscal Year: 2003
    ..These relationships will be evaluated in the context of the clinical status of each patient group to be studied, and in comparison to HIV-uninfected subjects. ..
  49. HCV Genomic Variability in HIV Infected Hemophiliacs
    Kenneth Sherman; Fiscal Year: 2004
    ..Treatment nonresponders will be followed in a prospective cohort study for up to 3 additional years so that the evolution of the virus, and its associated immune response in this group can be evaluated. ..
  50. Nucleoside analogs, mitochondria and AIDS cardiomyopathy
    William Lewis; Fiscal Year: 2006
    ..AIM 2: to define CM from HAART microscopically and ultrastructurally using morphometric methods. AIM 3: to define cardiac performance in CM from HAART echocardiographically and using Langendorff preparations. ..
  51. Fetal membrane fibroblasts:Proliferation/collagen synth
    MARK PLESSINGER; Fiscal Year: 2004
    ..This research on fibroblasts from the amnion and from the chorion would lead to an understanding of responses to fibroblast modulators, which are present in the fetal membrane during pregnancy. ..
  52. CNS specific Knock-out and Multidrug Transport
    RODNEY HO; Fiscal Year: 2006
    ..The potential benefits to overall biomedical research outweigh the calculated risks associated with this exploratory research. ..
  53. TULANE/LSU PEDIATRIC AIDS CLINICAL TRIALS UNIT
    Russell Van Dyke; Fiscal Year: 2006
    ..Finally, we will continue to provide leadership in the areas of perinatal transmission of HIV, the complications of HIV infection, adolescent medicine, and behavioral issues such as adherence to therapy. ..
  54. Pediatric Clinical Trials Program for AIDS
    William Shearer; Fiscal Year: 2006
    ..g., Cardiovascular Complications of HIV Infection]) with over 1OO participating professionals give BCM the potential to exceed its past strong role in carrying out the scientific agenda of the PACTG. ..
  55. Drug susceptibility assay for non-subtypr B HIV-1
    Neil Parkin; Fiscal Year: 2006
    ....
  56. ROLE OF MULTIDRUG RESISTANCE MUTATION IN HIV FITNESS
    Prem Sharma; Fiscal Year: 2002
    ..It has been demonstrated that didanosine (ddI)-induced mutation L74V and 3TC-selected mutation M184V render a replication disadvantage to the virus and ..
  57. Tulane/LSU HIV/AIDS Clinical Trials Networks Unit
    Russell Van Dyke; Fiscal Year: 2007
    ..unreadable] [unreadable] ADMINISTRATIVE COMPONENT: [unreadable] [unreadable] [unreadable]..